Tag Archive for: Stress Urinary Incontinence

Highlighting the need for a therapeutic solution in Stress Urinary Incontinence during World Continence Week

Optimum Strategic Communications is pleased to support Versameb during World Continence Week, a company raising awareness of the high unmet medical need of patients suffering with Stress Urinary Incontinence (SUI) and continence related issues which impacts the lives of millions of patients worldwide. Versameb’s Chief Executive Officer, Klaas Zuideveld to present on the Company’s proprietary […]

Versameb to Present during World Continence Week 2022

Lead therapeutic candidate has the potential to treat Stress Urinary Incontinence Raising awareness of the high unmet medical need of patients Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, is pleased to announce that Chief Executive Officer Klaas Zuideveld and Clinical Advisor Prof. Roger Dmochowski will be presenting Versameb’s lead therapeutic candidate, […]

The promise of mRNA therapeutics in producing the first regenerative treatment for SUI

Article by Dr Roger Dmochowski, Professor of Urology & Advisory Board Member of Versameb

Touchlight and Versameb announce GMP manufacturing supply agreement

Versameb moves forward with its lead asset towards clinical development with an Innovative synthetic doggybone DNA technology which increases quality and yield of mRNA therapeutics production Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing pipeline agreement with Versameb AG, an innovative pre-clinical stage […]

Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting

Data demonstrates first-in-class potential as a regenerative treatment of Stress Urinary Incontinence Treatment results in muscle regeneration with restored functionality in pre-clinical models Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its  Chief Scientific Officer, Friedrich Metzger will be presenting data on the Company’s mRNA […]